Survodutide
Survodutide (Dual GLP-1/Glucagon Receptor Agonist)
Investigational dual-action agonist targeting both GLP-1 and glucagon receptors by Boehringer Ingelheim. The glucagon component may enhance fat burning and energy expenditure beyond GLP-1-only drugs. Being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis).
📊 Evidence by Outcome
Weight loss
3 studies • Consistency: Moderate • Effect: Moderate
Liver fat reduction
3 studies • Consistency: Moderate • Effect: Moderate
Improved metabolic markers
3 studies • Consistency: Moderate • Effect: Moderate
Enhanced fat oxidation
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 1 Citations
Survodutide Phase 2 for Obesity
••2024
Key Finding: Up to 18.7% body weight reduction at 46 weeks in phase 2 trial with dose-dependent efficacy
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
TBD (not yet approved)
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.